胃食道癌におけるPF-08634404と呼ばれる研究用医薬品と化学療法との併用に関する研究
化学療法との併用によるPF-08634404の第2/3相介入試験:局所進行または転移性胃腺癌、胃食道接合部腺癌、または食道腺癌を有する未治療参加者を対象として
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
California
-
Atascadero、California、アメリカ、93422
- 募集
- UCLA Hematology/Oncology - Atascadero
-
Burbank、California、アメリカ、91505
- 募集
- UCLA Hematology/Oncology - Burbank
-
Encino、California、アメリカ、91436
- 募集
- UCLA Hematology/Oncology - Encino
-
Marina del Rey、California、アメリカ、90292
- 募集
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch、California、アメリカ、91326
- 募集
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco、California、アメリカ、94158
- まだ募集していません
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco、California、アメリカ、94158
- まだ募集していません
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo、California、アメリカ、93401
- 募集
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara、California、アメリカ、93101
- 募集
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica、California、アメリカ、90404
- 募集
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Boulder、Colorado、アメリカ、80303
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Centennial、Colorado、アメリカ、80112
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs、Colorado、アメリカ、80907
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs、Colorado、アメリカ、80923
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Denver、Colorado、アメリカ、80218
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Denver、Colorado、アメリカ、80220
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Englewood、Colorado、アメリカ、80113
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Lakewood、Colorado、アメリカ、80228
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Littleton、Colorado、アメリカ、80120
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree、Colorado、アメリカ、80124
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Longmont、Colorado、アメリカ、80504
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Pueblo、Colorado、アメリカ、81003
- 募集
- Rocky Mountain Cancer Centers, LLP
-
Thornton、Colorado、アメリカ、80260
- 募集
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach、Florida、アメリカ、32117
- まだ募集していません
- Florida Cancer Specialists
-
Fleming Island、Florida、アメリカ、32003
- まだ募集していません
- Florida Cancer Specialists
-
Palm Beach Gardens、Florida、アメリカ、33410
- まだ募集していません
- Florida Cancer Specialists
-
Sebring、Florida、アメリカ、33870
- まだ募集していません
- Florida Cancer Specialists
-
Wellington、Florida、アメリカ、33414
- まだ募集していません
- Florida Cancer Specialists
-
West Palm Beach、Florida、アメリカ、33401
- まだ募集していません
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights、Illinois、アメリカ、60005
- 募集
- Illinois Cancer Specialists
-
Bloomington、Illinois、アメリカ、61704
- 募集
- Illinois CancerCare - Bloomington
-
Chicago、Illinois、アメリカ、60631
- 募集
- Illinois Cancer Specialists
-
Galesburg、Illinois、アメリカ、61401
- 募集
- Illinois CancerCare - Galesburg
-
Niles、Illinois、アメリカ、60714
- 募集
- Illinois Cancer Specialists
-
Ottawa、Illinois、アメリカ、61350
- 募集
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin、Illinois、アメリカ、61554
- 募集
- Illinois CancerCare-Pekin
-
Peoria、Illinois、アメリカ、61615
- 募集
- Illinois CancerCare, P.C.
-
Peru、Illinois、アメリカ、61354
- 募集
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington、Illinois、アメリカ、61571
- 募集
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis、Maryland、アメリカ、21401
- 募集
- Maryland Oncology Hematology, P.A.
-
Bethesda、Maryland、アメリカ、20817
- 募集
- Maryland Oncology Hematology, P.A.
-
Brandywine、Maryland、アメリカ、20613
- 募集
- Maryland Oncology Hematology, P.A.
-
Columbia、Maryland、アメリカ、21044
- 募集
- Maryland Oncology Hematology, P.A.
-
Germantown、Maryland、アメリカ、20876
- 募集
- Maryland Oncology Hematology, P.A.
-
Largo、Maryland、アメリカ、20774
- 募集
- Maryland Oncology Hematology, P.A.
-
Rockville、Maryland、アメリカ、20850
- 募集
- Maryland Oncology Hematology, P.A.
-
Silver Spring、Maryland、アメリカ、20904
- 募集
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Regional Medical Center
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Health Medical Oncology
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown、New Jersey、アメリカ、07960
- まだ募集していません
- Atlantic Health System
-
Summit、New Jersey、アメリカ、07901
- まだ募集していません
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City、New York、アメリカ、11101
- 募集
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City、New York、アメリカ、11101
- 募集
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York、New York、アメリカ、10021
- 募集
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York、New York、アメリカ、10022
- 募集
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45245
- 募集
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati、Ohio、アメリカ、45242
- 募集
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati、Ohio、アメリカ、45211
- 募集
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield、Ohio、アメリカ、45014
- 募集
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem、Pennsylvania、アメリカ、19020
- 募集
- Alliance Cancer Specialists, PC
-
Doylestown、Pennsylvania、アメリカ、18901
- 募集
- Alliance Cancer Specialists, PC
-
Horsham、Pennsylvania、アメリカ、19044
- 募集
- Alliance Cancer Specialists, PC
-
Langhorne、Pennsylvania、アメリカ、19047
- 募集
- Alliance Cancer Specialists, PC
-
Media、Pennsylvania、アメリカ、19063
- 募集
- Alliance Cancer Specialists, PC
-
Sellersville、Pennsylvania、アメリカ、18960
- 募集
- Alliance Cancer Specialists, PC
-
Wynnewood、Pennsylvania、アメリカ、19096
- 募集
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving、Texas、アメリカ、75063
- 募集
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington、Virginia、アメリカ、22201
- 募集
- Virginia Cancer Specialists, PC
-
Chesapeake、Virginia、アメリカ、23320
- 募集
- Virginia Oncology Associates
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Virginia Cancer Specialists, PC
-
Hampton、Virginia、アメリカ、23666
- 募集
- Virginia Oncology Associates
-
Manassas、Virginia、アメリカ、20110
- 募集
- Virginia Cancer Specialists, PC
-
Newport News、Virginia、アメリカ、23606
- 募集
- Virginia Oncology Associates
-
Norfolk、Virginia、アメリカ、23502
- 募集
- Virginia Oncology Associates
-
Reston、Virginia、アメリカ、20190
- 募集
- Virginia Cancer Specialists, PC
-
Virginia Beach、Virginia、アメリカ、23456
- 募集
- Virginia Oncology Associates
-
Woodbridge、Virginia、アメリカ、22191
- 募集
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- 募集
- University of Washington Medical Center
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Center
-
Seattle、Washington、アメリカ、98104
- 募集
- Harborview Medical Center
-
-
-
-
Central District
-
Petah Tikva、Central District、イスラエル、4941492
- 募集
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan、HA Merkaz、イスラエル、5265601
- 募集
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv、TELL ABĪB、イスラエル、6423906
- 募集
- Sourasky Medical Center
-
-
-
-
-
Milan、イタリア、20141
- 募集
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- まだ募集していません
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
Barcelona [barcelona]
-
Barcelona、Barcelona [barcelona]、スペイン、08035
- 募集
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、スペイン、28041
- 募集
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense、Ourense [orense]、スペイン、32005
- まだ募集していません
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
-
Paris、フランス、75015
- 募集
- Hôpital Européen Georges Pompidou
-
-
-
-
-
Bayamón、プエルトリコ、00959
- 募集
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati、United States、プエルトリコ、00674
- 募集
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510655
- 募集
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan、Hubei、中国、430079
- 募集
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200031
- 募集
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 募集
- Sichuan Cancer hospital
-
-
-
-
-
Tainan、台湾、704302
- 募集
- National Cheng Kung University Hospital
-
Taipei、台湾、10002
- 募集
- National Taiwan University Hospital
-
Taipei、台湾、11217
- 募集
- Taipei Veterans General Hospital
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- 募集
- Aichi Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
他の名前:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
実験的:Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
他の名前:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
アクティブコンパレータ:Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
時間枠:Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
時間枠:Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
時間枠:Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
時間枠:Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
第2相:PF-08634404に対する抗薬物抗体(ADA)の発生率
時間枠:約21ヶ月
|
約21ヶ月
|
|
|
第3相:PF-08634404に対するADAの発生率
時間枠:約21ヶ月
|
約21ヶ月
|
|
|
第3相:Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) 総合スコアのベースラインからの変化
時間枠:約4年
|
約4年
|
|
|
第3相:FACT-Ga総合スコアの確定的悪化までの時間
時間枠:約4年間
|
約4年間
|
|
|
第3相:胃癌サブスケール(GaCS)スコアの明確な悪化までの時間
時間枠:約4年
|
約4年
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
時間枠:Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
時間枠:Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
時間枠:Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
時間枠:Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
時間枠:Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
時間枠:Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
時間枠:Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
時間枠:Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
時間枠:Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
時間枠:Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
時間枠:Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
時間枠:Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
時間枠:Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
時間枠:Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- C6461016
- 2025-524717-86-00 (レジストリ識別子:CTIS (EU))
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。